Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Baxter InternationalBAX -1.35%70 Revenue per Share is $22.27 as of Jun. 2026. GuruFocus rates BAX with a GF Score™ of 70/100 and a GF Value™ of $33.03 (Modestly Undervalued). The stock has 6 warning signs investors should review. Among 758 Medical Devices & Instruments companies, Baxter International ranks worse than 51.06% on this metric.
Baxter International's revenue per share for the
three
months ended in Jun. 2026 was $5.71.
Baxter International's revenue per share for the trailing twelve months (TTM) ended in Jun. 2026 was $22.27.
Warning Sign:
Baxter International Inc revenue per share has been in decline for the last 5 years.
During the past 12 months, the average Revenue Per Share Growth Rate of Baxter International was 5.00% per year.
During the past 3 years, the average Revenue Per Share Growth Rate was 3.20% per year.
During the past 5 years, the average Revenue Per Share Growth Rate was -1.50% per year.
During the past 10 years, the average Revenue Per Share Growth Rate was 1.50% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get other companies' revenue growth rate.
The historical rank and industry rank for Baxter International's Revenue per Share or its related term are showing as below:
BAX'
s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -32.2 Med: 3.8 Max: 29.3
Current: 3.2
During the past 13 years, Baxter International's highest 3-Year average Revenue Per Share Growth Rate was 29.30% per year. The lowest was -32.20% per year. And the median was 3.80% per year.
BAX's 3-Year Revenue Growth Rate is ranked worse than 51.06% of 758
companies
in the Medical Devices & Instruments industry
Industry Median: 3.7
vs BAX: 3.20
His favorite companies are stalwart, those growing between 10-20% a year.
Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.
Be Aware
Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.
Baxter International Revenue per Share Related Terms
Baxter International Revenue per Share Historical Data
* Premium members only.
The historical data trend for Baxter International's Revenue per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BAX vs COO, SOLV, ALGN: Revenue per Share Comparison
For the Medical Instruments & Supplies subindustry, Baxter International's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Baxter International PS Ratio vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Baxter International's PS Ratio distribution charts can be found below:
* The bar in red indicates where Baxter International's PS Ratio falls into.
Baxter International Revenue per Share Calculation
Revenue per Share is the amount of Revenue per outstanding share of the company's stock.
Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.
Baxter International's Revenue Per Share for the fiscal year that ended in Dec. 2025 is calculated as
Revenue per Share for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $22.27
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Baxter International (BAX) has a Revenue per Share of $22.27 as of Jun. 2026. Revenue per share equals the per-share value of a company's sales. View historical data on Baxter International and its competitors. According to the industry distribution chart, Baxter International ranks #387 out of 758 companies in the Medical Devices & Instruments industry, placing it in the top 51.1%.
Is Baxter International's Revenue per Share too high?
Baxter International's current Revenue per Share is $22.27. The Medical Devices & Instruments industry median Revenue per Share is 3.70. Baxter International's value of $22.27 is 501.9% above this industry median. Based on the distribution chart, Baxter International ranks #387 out of 758 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Baxter International has a GF Score™ of 70/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Baxter International's Revenue per Share compare to COO and SOLV?
According to the Medical Devices & Instruments industry distribution chart, Baxter International ranks #387 out of 758 companies for Revenue per Share. This places Baxter International in the lower half of its industry. The industry median Revenue per Share is 3.70. Baxter International's value of $22.27 is 501.9% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Revenue per Share for a Medical Devices & Instruments company?
The median Revenue per Share among Medical Devices & Instruments companies is 3.70, based on 758 companies in the industry. Companies in the top quartile (top 25%) have a Revenue per Share significantly above this median, while those in the bottom quartile fall well below. However, Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Baxter International's current Revenue per Share of $22.27 is 501.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Revenue per Share mean?
A high Revenue per Share can signal that a stock is expensive relative to its fundamentals. Revenue per share equals the per-share value of a company's sales. View historical data on Baxter International and its competitors. For the Medical Devices & Instruments industry, the median Revenue per Share is 3.70 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Baxter International's current Revenue per Share is $22.27. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Baxter International stock overvalued right now?
Based on GuruFocus' analysis, Baxter International (BAX) is currently considered Modestly Undervalued. The stock's GF Value™ is $33.03, compared to a current price of $24.06 — trading 27.2% below its estimated fair value. The current Revenue per Share is $22.27 and 501.9% above the Medical Devices & Instruments industry median of 3.70. Baxter International's overall GF Score™ is 70/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Revenue per Share calculated?
Revenue per Share is calculated from a company's financial statements. For Baxter International (BAX), the current Revenue per Share is $22.27 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Baxter International (BAX) Overvalued in 2026?
Based on GuruFocus' analysis, Baxter International stock appears to be undervalued.
The current stock price of $24.06 is trading 27.2% below its estimated GF Value™ of $33.03.
GuruFocus considers Baxter International to be Modestly Undervalued.
Key valuation signals for BAX:
Revenue per Share: $22.27
GF Value™: $33.03 vs. price of $24.06 (27.2% below fair value)
Industry Position: 501.9% above the Medical Devices & Instruments median (#387 of 758)
No single metric tells the full story. See the BAX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Baxter offers a variety of medical supplies and equipment to providers. From its legacy operations, Baxter sells injectable therapies for use in care settings, including IV pumps, administrative sets, and solutions; nutritional products; and surgical sealants and hemostatic agents. Baxter expanded its portfolio of hospital-focused offerings by acquiring Hillrom in late 2021, which added basic equipment like hospital beds, operating room equipment, and patient monitoring tools to the portfolio. Baxter also sold its kidney care tools in early 2025.
70GF Score
Get the complete analysis for BAX
Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BAX has been successfully added to your 
